Singapore markets closed

Dalrada Corporation (DFCO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.7650-0.0100 (-1.29%)
At close: 03:48PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.7750
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.7200 - 0.7900
52-week range0.1000 - 0.8400
Avg. volume124,175
Market cap57.927M
Beta (5Y monthly)7.67
PE ratio (TTM)N/A
EPS (TTM)-0.0200
Earnings date10 Feb 2022 - 14 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Dalrada Corporation Appoints Harvey Hershkowitz as President of Dalrada Health

    SAN DIEGO, November 22, 2021--Dalrada Corporation (OTCQB: DFCO, "Dalrada") is announcing to its shareholders and the public that Harvey Hershkowitz, Director, was appointed as President of its subsidiary Dalrada Health. Mr. Hershkowitz's prominent career in the healthcare industry spans more than 35 years, during which he served as Chairman on many boards. This broad perspective provides Dalrada Health with a significant advantage in implementing its current initiatives and expanding its capabil

  • Business Wire

    Dalrada Corporation Reports Strongest Quarter With 506% Increase in Revenue and 48% Reduction in Stockholder Deficit

    SAN DIEGO, November 19, 2021--Dalrada Corporation (OTCQB: DFCO, "Dalrada") has reported financial results for the quarter ending September 30th, 2021 (Fiscal Q1). The Company reported revenues of $4,602,353, representing an increase of 506% compared to $759,393 for the same quarter in 2020. Gross profit for the quarter was $3,398,018 compared to $525,965 for the quarter ending September 30th, 2020, representing a 546% increase.

  • Business Wire

    Dalrada Health Opens New Therapy Center and Advanced Testing Laboratory, Further Expanding Operations

    SAN DIEGO, November 11, 2021--Dalrada Corporation (OTCQB: DFCO, "Dalrada") proudly announces the openings of Dalrada Health's two new West Coast facilities with Sòlas Rejuvenation + Wellness ("Sòlas") and Empower Genomics' state-of-the-art testing laboratory.